Self-Injection Devices

Global Self-Injection Devices Market to Reach US$38.6 Billion by 2030

The global market for Self-Injection Devices estimated at US$22.1 Billion in the year 2024, is expected to reach US$38.6 Billion by 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Needle-free injectors, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$19.7 Billion by the end of the analysis period. Growth in the Autoinjectors segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.0 Billion While China is Forecast to Grow at 13.7% CAGR

The Self-Injection Devices market in the U.S. is estimated at US$6.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.0 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Self-Injection Devices Market – Key Trends & Drivers Summarized

Why Are Self-Injection Devices Revolutionizing Drug Delivery?

Self-injection devices are transforming the way patients manage chronic diseases, enabling convenient, precise, and minimally invasive drug administration. These devices, including auto-injectors, pen injectors, and wearable drug delivery systems, allow patients to self-administer medications for diabetes, rheumatoid arthritis, multiple sclerosis, and other conditions without requiring frequent clinic visits. The growing preference for home-based care and patient autonomy is driving demand for self-injection solutions. Additionally, the rise of biologic drugs, which require subcutaneous or intramuscular administration, is fueling the market for advanced injection devices.

What Innovations Are Improving The Performance Of Self-Injection Devices?

The self-injection devices industry is benefiting from significant advancements in drug delivery technologies. Smart self-injection systems equipped with Bluetooth connectivity and mobile health (mHealth) integration are enabling patients to track dosage history and receive real-time reminders. Needle-free injectors, which use high-pressure jet delivery, are emerging as pain-free alternatives to traditional needle-based devices. Auto-injectors with ergonomic designs and customizable dose settings are improving patient compliance. Additionally, biocompatible materials and sustainable packaging are being introduced to align with eco-friendly healthcare trends.

Which Healthcare Sectors Are Leading The Adoption Of Self-Injection Devices?

The diabetes sector is the largest consumer of self-injection devices, with insulin pens and continuous glucose monitoring (CGM)-linked injectors becoming the standard. The autoimmune disease segment, including rheumatoid arthritis and psoriasis, is witnessing increased adoption of biologic drug delivery via self-injectors. Oncology treatments are incorporating self-injection devices for at-home chemotherapy and immunotherapy regimens. Additionally, the growing trend of self-administered vaccines, such as flu and COVID-19 boosters, is expanding the scope of self-injection technologies.

What Factors Are Fueling The Growth Of The Self-Injection Devices Market?

The growth in the self-injection devices market is driven by the increasing prevalence of chronic diseases, advancements in biologic drug formulations, and the shift toward patient-centric healthcare. Regulatory approvals for innovative self-injection systems, along with growing investments in digital health and remote patient monitoring, are further boosting market adoption. Additionally, government initiatives promoting self-care and medication adherence are driving awareness and acceptance of self-injection solutions. As the demand for personalized medicine and home healthcare continues to expand, the self-injection devices market is expected to experience significant growth.

SCOPE OF STUDY:

The report analyzes the Self-Injection Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Needle-free injectors, Autoinjectors, Pen injectors, Wearable injectors); Usability (Disposable, Reusable); Application (Cancer, Autoimmune disorders, Hormonal disorders, Pain management, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Antares Pharma Inc. (now part of Halozyme Therapeutics)
• ApiJect Systems Corporation
• Becton, Dickinson and Company (BD)
• Biocorp Production SA
• Biogen Inc.
• Elcam Medical
• Eli Lilly and Company
• Ferring Pharmaceuticals
• Gerresheimer AG
• Halozyme Therapeutics, Inc.
• Haselmeier (a medmix Brand)
• Haselmeier GmbH
• Insulet Corporation
• Medtronic PLC
• Mylan N.V. (now part of Viatris)
• Novartis AG
• Novo Nordisk A/S
• NuGen Medical Devices
• Owen Mumford Ltd.
• Pfizer Inc.
• Recipharm AB
• Sanofi
• SHL Group
• SHL Medical
• UCB S.A.
• Union Medico
• West Pharmaceutical Services
• Ypsomed AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.